RecruitingNot ApplicableNCT02808572
New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients
New Biomarkers of Bone and Mineral Metabolism as Risk Factors for Morbidity/Mortality in Chronic Kidney Disease Patients Not Requiring Dialysis
Sponsor
University Hospital, Montpellier
Enrollment
250 participants
Start Date
Mar 12, 2013
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.
Eligibility
Min Age: 18 YearsMax Age: 95 Years
Inclusion Criteria2
- Patient who has signed the written consent form
- Patient with chronic renal failure defined by glomerular filtration rate (GFR) but without dialysis therapy
Exclusion Criteria2
- Pregnancy
- Patient with chronic renal failure requiring dialysis therapy
Interventions
BIOLOGICALPlasma osteoprotegerin level
dosage of plasma osteoprotegerin
BIOLOGICALPlasma fibroblast growth factor 23 level
dosage of plasma fibroblast growth factor 23
PROCEDUREVascular calcification score
measurement of vascular calcification score by multidetection computerized tomography
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02808572
Related Trials
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
NCT06926660153 locations
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945102 locations
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283178 locations
An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea
NCT072325371 location
Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care
NCT071694221 location